Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation

Leukemia

Volumn 10, Issue 6, 1996, Pages 1054-1064

  James, H ^a   Mills, K ^b   Gibson, I ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Bcr abl; CML; Hammerhead ribozymes; Specificity

Indexed keywords

BCR ABL PROTEIN; MESSENGER RNA; MUTANT PROTEIN; RIBOZYME;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME STRUCTURE; PRIORITY JOURNAL; RNA CLEAVAGE; RNA SEQUENCE; STRUCTURE ACTIVITY RELATION;

EID: 0030056108     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Clark SS, Crist WM, Witte ON. Molecular pathogenesis of Ph-positive leukemias. Annu Rev Med 1989; 40: 113-122.
2. Bernards A, Rubin CM, Westbrook CA, Paskind M, Baltimore D. The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia. Mol Cell Biol 1987; 7: 3231-3236.
3. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-99.
4. Konopka JB, Witte ON. Detection of c-abl tyrosine kinase-activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 1985; 5: 3116-3123.
5. Lugo TG, Pendergast A-M, Muller AJ and Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-1082.
6. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210bcr/abl protein. Proc Natl Acad Sci USA 1988; 85: 9312-9316.
7. bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
8. Elefanty AG, Hariharan IK, Cory S. BCR-ABL, the hallmark of chronic myeloid leukemia in man, induces multiple hematopoietic neoplasms in mice. EMBO J 1990; 9: 1069-1078.
9. Kelliher MA, McLaughlin J, Witte ON, Rosenberg M. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr/abl. Proc Natl Acad Sci USA 1990; 87: 6649-6653.
10. BCR-ABL expression and inhibit the proliferation of BCR/ABL containing cell-lines. Blood 1993; 81: 502-509.
11. Smetsers TFCM, Skorski T, van de Locht LTF, Wessels HMC, Pennings AHM, de Witte T, Calabreta B, Mensink EJBM. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 1994; 8: 129-140.
12. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B. Suppression of Philadelphia-leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1994; 91: 4504-4508.
13. Citro G, Szczylik C, Ginobbi P, Zupi G, Calabretta B. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL60 cells. Br J Cancer 1994; 69: 463-467.
14. Gewirtz AM, Calabretta B. A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science 1988; 242: 1303-1306.
15. Degols G, Leonetti J-P, Mechti N, Lebleu B. Antiproliferative effects of antisense oligonucleotides directed to the RNA of c-myc oncogene. Nucleic Acids Res 1991; 19: 945-948.
16. Giles RV, Spiller DG, Tidd DM. Detection of ribonuclease H generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res Dev 1995; 5: 23-31.
17. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988; 334: 585-591.
18. Forster AC, Symons RH. Self-cleavage of plus and minus RNAs of avirusoid and a structural model for the active sites. Cell 1987; 49: 211-220.
19. Hutchins CJ, Rathjen PD, Forster AC, Symons RH. Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucleic Acids Res 1986; 14: 3627-3640.
20. Uhlenbeck OC. A small catalytic oligoribonucleotide. Nature 1987; 328: 596-600.
21. Perriman R, Delves A, Gerlach WL. Extended target-site specificity for a hammerhead ribozyme. Gene 1992; 113: 157-163.
22. Zoumadakis M, Tabler M. Comparative analysis of cleavage rates after systematic permutation of the NUXi consensus target motif for hammerhead ribozymes. Nucleic Acids Res 1995; 23: 1192-1196.
23. Lange W, Cantin EM, Finke J, Dolken G. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 1993; 7: 1786-1794.
24. Shore SK, Nabissa DM, Reddy EP. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of p210 protein-kinase activity. Oncogene 1993; 8: 3183-3188.
25. Kearney PP, Wright LA, Milliken S, Biggs JC, Wilson SB. Ribozyme and antisense DNA regulation of bcr/abl expression in CML patients. J Cell Biochem 1994; 18A: 233.
26. Leopold LH, Shore SK, Newkirk TA, Reddy RMV, Reddy EP. Multiunit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood 1995; 85: 2162-2170.
27. Pachuk CJ, Yoon K, Moelling K, Coney LR. Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences. Nucleic Acids Res 1994; 22: 301-307.
28. Wright L, Wilson SB, Milliken S, Biggs J, Kearney P. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia. Exp Hematol 1993; 21: 1714-1718.
29. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 1975; 45: 321-334.
30. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
31. Sambrook J, Fritsch EF, Maniatis T, (Eds). Molecular Cloning, a Laboratory Manual. Cold Spring Harbour Laboratory Press: Cold Spring Harbor, NY, 1989.
32. Fu D-J, McLaughlin LW. Importance of specific purine amino and hydroxyl groups for efficient cleavage by a hammerhead ribozyme. Proc Natl Acad Sci USA 1992; 89: 3985-3989.
33. Williams DM, Pieken WA, Eckstein F. Function of specific 2′-hydroxyl groups of guanosines in a hammerhead ribozyme probed by 2′ modifications. Proc Natl Acad Sci USA 1992; 89: 918-921.
34. Student (Gosset WS). The probable error of a mean. Biometrika 1908; 6: 1-25.
35. Tabler M, Homann M, Tzortzakaki S, Sczakiel G. A three nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design. Nucleic Acids Res 1994; 22: 3958-3965.
36. Zoumadakis M, Neubert WJ, Tabler M. The influence of imperfectly paired helices I and III on the catalytic activity of hammerhead ribozymes. Nucleic Acids Res 1994; 22: 5271-5278.
37. Hertel KJ, Pardi A, Uhlenbeck OC, Koizumi M, Ohtsuka E, Uesugi S, Cedergren R, Eckstein F, Gerlach WL, Hodgson R, Symons RH. Numbering system for the hammerhead. Nucleic Adds Res 1992; 20: 3252.
38. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligonucleotides. Science 1991; 253: 562-565.
39. bcrabl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res 1994; 22: 2150-2154.
40. Bergen RC, Kyle E, Connell Y, Neckers L. Inhibition of protein-kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Res Dev 1995; 5: 33-38.
41. Kirkland MA, O'Brien SG, McDonald C, Davidson RJ, Cross NCP, Goldman JM. BCR-ABL antisense purging in chronic myeloid leukaemia. Lancet 1993; 342: 614.
42. O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM. Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia 1994; 8: 2156-2162.
43. Thomas M, Kosciolek B, Wang N, Rowley P. Capping of bcr-abl antisense oligonucleotides enhances anti-proliferative activity against chronic myeloid leukemia cell lines. Leuk Res 1994; 18: 401-408.
44. Tari AM, Tucker SD, Deisseroth A, Lopez-Berestein G. Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood 1994; 84: 601-607.
45. Snyder DS, Wu Y, Wang JL, Rossi JJ, Swiderski P, Kaplan BE, Forman SJ. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 1993; 82: 600-605.
46. Mahone FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp Hematol 1995; 23: 1608-1611.
47. Woisard A, Fourrey J-L, Favre A. Multiple folded conformations of a hammerhead ribozyme domain under cleavage conditions. J Mol Biol 1994; 239: 366-370.
48. Pley HW, Flaherty KM, Mckay DB. Three dimensional structure of a hammerhead ribozyme. Nature 1994; 372: 68-74.
49. Tuschl T, Gohlke C, Jovin TM, Westhof E, Eckstein F. 3-Dimensional model for the hammerhead ribozyme based on fluorescence measurements. Science 1994; 266: 785-789.
50. Goodchild J, Kohli V. Ribozymes that cleave an RNA sequence from human immunodeficiency virus: the effect of flanking sequence on rate. Arch Biochem Biophys 1991; 284: 386-391.
51. Herschlag D. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc Natl Acad Sci USA 1991; 88: 6921-6925.
52. Tsuchihashi Z, Khosla M, Herschlag D. Protein enhancement of hammerhead ribozyme catalysis. Science 1993; 262: 99-102.
53. Bertrand EL, Rossi JJ. Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J 1994; 13: 2904-2912.
54. Herschlag D, Khosla M, Tsuchihashi Z, Karpel RL. An RNA chaperone activity of non-specific RNA binding proteins in hammerhead ribozyme catalysis. EMBO J 1994; 13: 2913-2924.
55. Zhao JJ, Pick L. Generating loss-of-function phenotypes of the fushi tarazu gene with a targeted ribozyme in Drosophila. Nature 1993; 365: 448-451.